| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 603108 | 润达医疗 | 14.83 | -0.20% | 6.15万 | 9143.29万 | | 000411 | 英特集团 | 11.29 | -0.18% | 3.42万 | 3848.23万 | | 600511 | 国药股份 | 28.63 | 0.00% | 3.67万 | 1.05亿 | | 002727 | 一六堂 | 13.88 | 0.14% | 1 5.59万 | 7764.85万 | | 301015 | 百洋医药 | 25.79 | 0.16% | 2.55万 | 6565.97万 | | 603368 | 柳药集团 | 18.58 | 0.16% | 5.06万 | 9391.76万 | | 601607 | 上海医药 | 18.20 | 0.28% | 12.66万 | 2.30亿 | | 600056 | 中国医药 | 10.98 | 0.37% | 16.54万 | 1.81亿 | | 000950 | 重 ...

从基金十大重仓股角度 10月20日，大参林涨5.2%，截至发稿，报18.41元/股，成交1.76亿元，换手率0.85%，总市值209.66亿 元。大参林股价已经连续4天上涨，区间累计涨幅5.29%。 资料显示，大参林医药集团股份有限公司位于广东省广州市荔湾区龙溪大道410号、410-1号，成立日期 1999年2月12日，上市日期2017年7月31日，公司主营业务涉及中西成药、参茸滋补药材及中药饮片、保 健品、医疗器械及其他商品的连锁零售业务。主营业务收入构成为：中西成药76.88%，非药品 10.49%，中参药材9.75%，其他(补充)2.88%。 中邮中证500指数增强A（590007）基金经理为王高。 截至发稿，王高累计任职时间5年106天，现任基金资产总规模17.04亿元，任职期间最佳基金回报 34.78%， 任职期间最差基金回报-29.36%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 数据显示，中邮基金旗下1只基金重仓大参林。中邮中证5 ...

Core Viewpoint - Dazhonglin Pharmaceutical Group Co., Ltd. reported strong financial results for the first half of 2025, achieving revenue of 13.522 billion yuan, a year-on-year increase of 1.33%, and a net profit of 798 million yuan, up 21.38% [1] Group 1: Financial Performance - The company’s net profit attributable to shareholders, excluding non-recurring gains and losses, was 788 million yuan, reflecting a growth of 19.73% [1] - Earnings per share were reported at 0.7 yuan, with a dividend payout of 0.34 yuan [1] - Cumulatively, the company has returned 3.834 billion yuan to shareholders through dividends and buybacks, surpassing the 3.394 billion yuan raised since its listing [1] Group 2: Industry Context - The overall retail market for physical pharmacies in China saw a decline of 2.2% in the first half of 2025, with health products down 18.6% and traditional Chinese medicine down 5.4% [2] - Despite the industry downturn, Dazhonglin achieved steady growth, attributed to its strategic planning and innovative business model [2] Group 3: Growth Drivers - The company’s success is largely due to its innovative "direct franchise" model and deepening digital transformation [3] - As of the reporting period, Dazhonglin operated a total of 16,833 stores across 21 provinces, with 10,370 direct stores and 6,463 franchise stores [3] - The "direct franchise" model, initiated in 2019, has become a core driver for rapid expansion, combining standardized management with franchise advantages [3] Group 4: Digital Transformation - Dazhonglin is implementing strategies focused on cost reduction, efficiency enhancement, and revenue generation through various digital initiatives [4] - The launch of "AI Xiaosan" has improved service efficiency and customer satisfaction by providing intelligent responses and analysis [4] - The company has developed a precise marketing system to deepen the value extraction of its membership base [4] Group 5: Future Outlook - Dazhonglin plans to continue its strategy of deepening its presence in South China while expanding nationwide, focusing on increasing market share in existing provinces [5] - The company aims to enhance its digital transformation and optimize supply chain management to solidify its leading position in the industry [5] - With the ongoing trends in population aging and the increasing value of retail pharmacy channels, Dazhonglin is well-positioned for sustained growth in 2025 [5]

Group 1 - The core viewpoint of the news is that Dazhonglin's stock has shown a positive trend, with a year-to-date increase of 18.44% and a recent uptick of 5.18% over the last five trading days [2] - As of October 16, Dazhonglin's stock price reached 17.47 CNY per share, with a total market capitalization of 19.896 billion CNY [1] - The company reported a revenue of 13.523 billion CNY for the first half of 2025, reflecting a year-on-year growth of 1.33%, while the net profit attributable to shareholders increased by 21.38% to 798 million CNY [2] Group 2 - Dazhonglin's main business segments include Western and Chinese medicines (76.88%), non-pharmaceutical products (10.49%), Chinese medicinal materials (9.75%), and other supplementary products (2.88%) [2] - The company has distributed a total of 3.355 billion CNY in dividends since its A-share listing, with 1.624 billion CNY distributed over the past three years [3] - As of June 30, 2025, the number of Dazhonglin's shareholders decreased by 10.07% to 31,500, while the average circulating shares per person increased by 11.20% to 36,097 shares [2]

证券代码：603233 证券简称：大参林 公告编号：2025-061 转债代码：113605 转债简称：大参转债 大参林医药集团股份有限公司 关于可转换公司债券2025年付息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 大参林医药集团股份有限公司（以下简称"公司"）于2020年10月22日公开发行的可转换公司债券（以下 简称"大参转债"）将于2025年10月22日开始支付自2024年10月22日至2025年10月21日期间的利息。根据 《大参林医药集团股份有限公司公开发行A股可转换公司债券募集说明书》（以下简称"《募集说明 书》"）有关条款的规定，现将有关事项公告如下： 7、票面金额和发行价格： 按面值发行，每张面值为人民币100元。 8、债券期限：本次发行的可转换公司债券的期限为自发行之日起6年，即2020年10月22日至2026年10月 21日。 9、债券利率：本次发行的可转换公司债券票面利率具体为：第一年0.30%、第二年0.60%、第三年 1.00%、第四年1.50%、第五年1.80%、第六年 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 转债代码：113605 转债简称：大参转债 证券代码：603233 证券简称：大参林 公告编号：2025-061 大参林医药集团股份有限公司 关于可转换公司债券 2025 年付息的公告 重要内容提示： 大参林医药集团股份有限公司（以下简称"公司"）于2020年10月22日公 开发行的可转换公司债券（以下简称"大参转债"）将于2025年10月22日开始支 付自2024年10月22日至2025年10月21日期间的利息。根据《大参林医药集团股份 有限公司公开发行A股可转换公司债券募集说明书》（以下简称"《募集说明书》"） 有关条款的规定，现将有关事项公告如下： 一、本期债券的基本情况 1、债券名称：大参林医药集团股份有限公司可转换公司债券 2、债券简称：大参转债 3、债券代码：113605 8、债券期限：本次发行的可转换公司债券的期限为自发行之日起 6 年，即 2020 年 10 月 22 日至 2026 年 10 月 21 日。 9、债券利率：本次发行的可转换公司债券票面利率具体为： ...

Market Overview - The pharmaceutical commercial sector increased by 0.17% on October 14, with Baiyang Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3865.23, down 0.62%, while the Shenzhen Component Index closed at 12895.11, down 2.54% [1] Stock Performance - Baiyang Pharmaceutical (301015) closed at 26.19, up 1.35% with a trading volume of 48,200 shares and a transaction value of 127 million [1] - China Pharmaceutical (600056) closed at 11.26, up 1.26% with a trading volume of 278,600 shares and a transaction value of 313 million [1] - Dazhenlin (603233) closed at 16.81, up 1.14% with a trading volume of 75,200 shares [1] - Other notable performers include Jianfa Zhixin (301584) up 1.01% and Renmin Tongtai (600829) also up 1.01% [1] Capital Flow - The pharmaceutical commercial sector experienced a net outflow of 129 million from institutional investors, while retail investors saw a net inflow of 209 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors are increasing their positions [2] Individual Stock Capital Flow - Saily Medical (603716) had a net inflow of 27.9 million from institutional investors, but a net outflow of 21.2 million from speculative funds [3] - Jianfa Zhixin (301584) saw a net inflow of 11.02 million from institutional investors, with a net outflow of 9.78 million from speculative funds [3] - Yifeng Pharmacy (603939) had a net inflow of 9.47 million from institutional investors, while retail investors experienced a net outflow of 13.37 million [3]

证券代码：603233 证券简称：大参林 公告编号：2025-060 转债代码：113605 转债简称：大参转债 ● 截至2025年9月30日，累计有362,000元"大参转债"转换为公司股份，占可转债发行总量的0.0258%； 累计转股数量6,242股，累计转股占可转债转股前公司已发行股份总额0.0009%。 ● 截至2025年9月30日，公司尚未转股的可转债金额为1,404,638,000元，占可转债发行总量的 99.9742%。 ● 2025年第三季度并无新增转股。 大参林医药集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： 2、转股价格：根据《大参林医药集团股份有限公司公开发行可转换公司债券募集说明书》发行条款以 及中国证监会关于可转换公司债券发行的有关规定，"大参转债"在本次发行之后，若公司发生派送红 股、转增股本、增发新股（不包括因本次发行的可转换公司债券转股而增加的股本）、配股以及派发现 金股利等情况，将对转股价格进行调整。 一、可转债发行上市概况 （ ...

证券代码：603233 证券简称：大参林 公告编号：2025-060 转债代码：113605 转债简称：大参转债 大参林医药集团股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、 可转债发行上市概况 （一） 可转债发行情况 大参林医药集团股份有限公司（以下简称"公司"）经中国证券监督管理委 员会证监许可[2020]1981号文核准，于2020年10月22日公开发行了14,050,000张 可转换公司债券，每张面值100元，发行总额为人民币140,500.00万元。经上海证 券交易所自律监管决定书【2020】370号文同意，可转换公司债券于2020年11月 13日起在上海证券交易所挂牌交易，债券简称"大参转债"，债券代码"113605"。 （二） 转股日期及转股价格 1、转股日期：公司本次发行的"大参转债"自2021年4月28日起可转换为公司 股份。 2、转股价格：根据《大参林医药集团股份有限公司公开发行可转换公司债 券募集说明书》发行条款以及中国证监会关于可转换公司 ...

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.11% on September 30, with C Jianfa leading the drop [1] - The Shanghai Composite Index closed at 3882.78, up 0.52%, while the Shenzhen Component Index closed at 13526.51, up 0.35% [1] Stock Performance - Notable gainers in the pharmaceutical sector included: - Baiyang Pharmaceutical (301015) with a closing price of 28.00, up 1.93% [1] - Saily Medical (603716) at 24.87, up 1.84% [1] - Guofa Co., Ltd. (600538) at 5.63, up 1.26% [1] - C Jianfa (301584) was the biggest loser, closing at 28.99, down 15.04% with a trading volume of 264,700 shares and a turnover of 817 million [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 239 million in main funds, while retail investors contributed a net inflow of 219 million [2][3] - The main funds showed varying net inflows and outflows across different stocks, with Saily Medical experiencing a net inflow of approximately 889,790 and Baiyang Pharmaceutical seeing a net inflow of 738,150 [3]